LS-102

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.

LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.

LS-102 (1.3-4 mg/kg；腹腔注射；每日一次，持续 4 周) 可降低 CIA 模型中的临床严重程度评分。Animal Model:7-week-old DBA/1 male mice (CIA model) Dosage:1.3, 4.0 mg/kg Administration:I.p.; daily for 4 weeks Result:Reduced the clinical severity scores.

LS-102 抑制 RSCs 的增殖，IC50 为 5.4 μM。 LS-102 抑制类风湿滑膜细胞 (RSCs) 的增殖Syvn1依赖方式。LS-102 抑制 Syvn1 靶蛋白的多泛素化，包括核因子红细胞 2 相关因子 2 (NRF2)、V247M α-肌聚糖突变体和 PGC-1β。LS-102 抑制 Synoviolin (Syvn1) 的 E3 连接酶活性。Cell Viability Assay Cell Line:Rheumatoid synovial cells (RSCs) m Concentration:20, 40, 60 μM Incubation Time:12 hours Result:Inhibited proliferation of RSCs with an IC50 of 5.4 μM.

———

Others

Other Targets

———

———

———

1456891-34-1

452.6

C24H36N8O

>98% (HPLC)

DMSO : 100 mg/mL (220.95 mM )

———

———

(-20℃)

With Ice Pack

≥ 2 years